BioSpace News Archive

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today provided an update on the preclinical results f

Novartis announced that new ofatumumab data from the Phase III ASCLEPIOS trials and the Phase II APLIOS trial were presented virtually at the 6th Congress of the European Academy of Neurology.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), specialists in custom antibody discovery and development, today announced a collaboration between University of Victoria (“UVic”)-based laboratory of Dr. Alexandre Brolo , experts in the development of novel diagnostic too

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, announced today the launch of InfectionWatch™, an infection surveillance and reporting solution that provides healthcare facilities with data-driven insights to empower real-time identification of infections demonstrating antibiotic resistance and virus outbreaks such as COVID-19. This reporting solution helps facilities meet regulatory compli

After almost 10 years of service as the CEO of Tegra Medical and as Head of the Medical division within the SFS Group, J. Mark King has decided to retire as of August 1, 2020 . The Board of Directors and the Group Executive Board thank J. Mark King for his many years of service, his contribution to the development of Tegra Medical

Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is scheduled to make a presentation at the Jefferies Virtual Healthcare Conference at 2:30 p.m. ET on Wednesday, June 3, 2020. Morphic will give an update on the Company’s progress across its portfolio of oral small mole

IntelGenx Corp. announced that the U.S. Food & Drug Administration has granted the Company’s request for a Type A meeting related to its RIZAPORT® VersaFilm® program.

Coverage Effective Immediately on One of the Largest Payor Networks in the U.S. AMZEEQ ® is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to Severe Acne BRIDGEWATER, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that its novel AMZEEQ ® (min

Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced the acquisition of Praha Vaccines a.s., part of the Cyrus Poonawalla Group, in an all cash transaction of approximately $167 million.

Imaging Endpoints announced that it has supported two additional U.S. Food and Drug Administration approvals this month for new, life-saving therapies.